Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H002 in Advanced EGFR-Mutated NSCLC
NCT05552781Phase 2Recruiting
- Sponsor
- RedCloud Bio
- Start
- Aug 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of maihuatinib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by RedCloud Bio. Primary endpoints: Incidence of dose-limiting toxicities at Cycle 1, Incidence and severity of treatment-emergent adverse events up to 30 months and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
maihuatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05552781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552781.